COMMUNIQUÉS West-GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
28/02/2024
Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
28/02/2024
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024 Received Orphan Drug Designation for LYL845 for the treatment of melanoma Expect to submit IND for [...]
Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 - Issues Fiscal Year 2024 Guidance
28/02/2024
Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-year Q4 2023 constant currency revenue* up 10.3% year-over-year Q4 2023 constant currency revenue, organic* up 8.3% year-over-year Q4 2023 GAAP operating [...]
Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
28/02/2024
SUNNYVALE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three [...]
Pennant Reports Fourth Quarter and Fiscal Year 2023 Results
28/02/2024
Conference Call and Webcast scheduled for tomorrow, February 29, 2024 at 10:00 am MT EAGLE, Idaho, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28/02/2024
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA ( 1 ) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ( 2 ) of $8.5 Million [...]
WW International, Inc. Announces Upcoming Oprah Winfrey Board Transition
28/02/2024
Continued Collaboration to Advocate for and Elevate Conversation on Weight Health Ms. Winfrey to Donate Financial Interest in WeightWatchers to the National Museum of African American History and Culture NEW YORK, Feb. [...]
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
28/02/2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance [...]
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
28/02/2024
Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory [...]
WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results
28/02/2024
Fourth Quarter 2023 End of Period Subscribers of 3.8 million, including 67 thousand End of Period Clinical Subscribers Revenues of $206.0 million Gross margin of 60.6%; excluding the net impact of restructuring charges [...]
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
28/02/2024
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28/02/2024
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28/02/2024
- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash position and [...]
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
28/02/2024
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
28/02/2024
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 [...]
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
28/02/2024
Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $ [...]
Vimient Launches Innovative Program With Regency Place Senior Living to Offer Enhanced Senior Care
28/02/2024
Synergistic partnership with Sacramento senior living community will enrich holistic wellness, personalized care and resident safety ROSEVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vimient – a leading provider of [...]
Janssen reçoit un avis favorable de la part du CMUH pour CARVYKTI®▼ (ciltacabtagène autoleucel ; cilta-cel) dans le traitement du myélome multiple en rechute et réfractaire en premières lignes
28/02/2024
Les résultats de l’étude de phase III CARTITUDE-4, qui étayent la recommandation du CMUH, ont démontré que le cilta-cel avait le potentiel d’offrir un bénéfice significatif aux patients en premières lignes de traitement [...]
The Kettle Society Welcomes Wayne Leslie as New Executive Director
28/02/2024
Following a comprehensive search, we are excited to announce the appointment of a new Executive Director with the planned retirement of long-serving ED, Nancy Keough. VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE [...]

Pages